ENLV does not have a deep bench of current, individually attributable price targets. The one consistently named view is H.C. Wainwright's Raghuram Selvaraju, who maintains a Buy rating. Before the reverse split, the firm raised its target to $1,280 in early August 2026; adjusting for the subsequent 1-for-16 reverse split, that figure lands near $80 per share. Aggregator sites display wildly inconsistent "consensus" numbers — $20, $80, $1,280, and even $4,800 — most of which reflect stale data or split-related errors rather than a genuine multi-analyst consensus.
Because there are not multiple credible, current individual targets to average, the $1.50 figure in this article is a fallback drawn from public technical discussion — specifically the medium-term resistance zone near $1.50–$1.52 shown in widely used technical screens — rather than an analyst price target or a calculated mean. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Enlivex shares last closed near $1.05. A move to $1.50 would require a gain of about 43%, which for a thinly traded microcap of roughly $2 million in market capitalization is a substantial move rather than a trivial step. The quoted 52-week range of roughly $1.00 to $434.40 is heavily distorted by the reverse splits and does not reflect genuine value creation over that period.
The most realistic path toward $1.50 would run through a stabilization of the share price, a favorable resolution of the Nasdaq listing appeal, and renewed buying interest tied to the Allocetra clinical program — rather than any single near-term catalyst.
The $1.00 level stands out as a psychological support zone near the recent low. On the upside, $1.30–$1.35 (the recent offering price) marks a first hurdle, followed by the medium-term resistance band around $1.50–$1.52 that anchors this article's target. Longer-term resistance sits higher, near $1.77, while moving averages well above the current price confirm a persistent downtrend in the stock's market structure.
Analyst price targets typically reflect a roughly 12-month research horizon, but with only one named analyst view and split-distorted data, that convention is of limited use here. Investors should instead watch the outcome of the Nasdaq delisting appeal, any new financing or dilution, Phase 2b Allocetra enrollment and data milestones, developments in the RAIN token treasury strategy, and the company's next earnings release (currently estimated for early December 2026).
For traders who prefer a systematic approach to a highly volatile name like this, Tickeron’s AI Daily Buy/Sell Signals offers a data-driven complement to manual research. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than scanning charts by hand. Exploring the signals for ENLV may add useful context to the levels discussed above. In my view, this kind of systematic input is especially helpful when traditional analyst coverage is thin and distorted.
The $1.50 target is a technical milestone, not an analyst consensus. Reaching it would require a roughly 43% advance from a base near $1.05 — substantial for a microcap facing dilution, listing uncertainty, and persistent selling pressure. The strongest supports are genuine clinical progress in the Allocetra program and evidence that some investors are willing to fund the company at a premium, while the heaviest obstacles remain dilution and the unresolved Nasdaq appeal. With analyst data too thin and distorted to offer a reliable aggregate, the practical question is less about a single price target and more about whether listing, financing, and clinical catalysts can first stabilize the shares around support near $1.00.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
On November 18, 2026, the Stochastic Oscillator for ENLV moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 57 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 83%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in 158 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ENLV entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.006) is normal, around the industry mean (3.596). P/E Ratio (0.001) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions
Industry Biotechnology